Zhejiang Nord Pharmaceutical Co., Ltd

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Marketing application approved: 2 applicationsAccepted: 8 applicationsNo longer listed under review: 2 applicationsSupplement delivery: 1 application

1. 2026/11/04No longer listed under review

   Ibrutinib Capsules

   CYHS2500657

   Fact date: 2026/11/04 · Site observation date: 2026/11/04

   Accepted: 2025/02/09

   not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked

   View source ↗
2. 2026/11/03No longer listed under review

   Apalutamide Tablets

   CYHB2601618

   Fact date: 2026/11/03 · Site observation date: 2026/11/03

   Accepted: 2026/08/25

   not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/02 (approval no.: —; approval date: 2026/10/30); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 4

   NMPA · Table row 4 ↗ View source ↗
3. 2026/11/03Accepted

   Telmisartan Tablets

   CYHS2602681

   Fact date: 2026/11/03 · Site observation date: 2026/11/04

   View source ↗
4. 2026/10/30Supplement delivery

   Apalutamide Tablets

   CYHB2601618

   Fact date: 2026/10/30 · Publication date: 2026/11/02 · Site observation date: 2026/11/03

   Supplemental application; excluded from new marketing approvals.

   View source · Table row 4 ↗
5. 2026/10/20Marketing application approved

   Vonoprazan Fumarate Tablets

   CYHS2500015 · 国药准字H20266341

   Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03

   View source · Table row 19 ↗
6. 2026/10/20Marketing application approved

   Vonoprazan Fumarate Tablets

   CYHS2500014 · 国药准字H20266340

   Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03

   View source · Table row 18 ↗
7. 2026/09/21Accepted

   Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ)

   CYHS2602366

   Fact date: 2026/09/21 · Site observation date: 2026/10/21

   View source ↗
8. 2026/08/28Accepted

   Valsartan and Amlodipine Tablets（I）

   CYHB2601649

   Fact date: 2026/08/28 · Site observation date: 2026/10/21

   View source ↗
9. 2026/08/25Accepted

   Apalutamide Tablets

   CYHB2601618

   Fact date: 2026/08/25 · Site observation date: 2026/10/21

   View source ↗
10. 2026/08/21Accepted

    Brivaracetam Tablets

    CYHS2602090

    Fact date: 2026/08/21 · Site observation date: 2026/10/21

    View source ↗
11. 2026/08/21Accepted

    Brivaracetam Tablets

    CYHS2602089

    Fact date: 2026/08/21 · Site observation date: 2026/10/21

    View source ↗
12. 2026/08/21Accepted

    Brivaracetam Tablets

    CYHS2602088

    Fact date: 2026/08/21 · Site observation date: 2026/10/21

    View source ↗
13. 2026/08/20Accepted

    Azilsartan Tablets

    CYHS2602071

    Fact date: 2026/08/20 · Site observation date: 2026/10/21

    View source ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

CDE acceptances and review

Last successful update: 2026/11/11 06:42

Chemical-drug catalogue

Last successful update: 2026/11/11 06:38

Full API register

Last successful update: 2026/11/11 06:40

NMPA drug delivery notices

Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete

First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Public drug landscapes ↗